Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and 18F-FDG PET fusion

Clinical Nuclear Medicine

Volumn 39, Issue 5, 2014, Pages

  Urban, Trinity ^a   Lim, Ruth ^a   Merker, Vanessa L ^a   Muzikansky, Alona ^a   Harris, Gordon J ^a   Kassarjian, Ara ^a,b   Bredella, Miriam A ^a   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Neurology and Cancer Center Yawkey Center for Outpatient Care ^*  (Spain)

Author keywords

malignancy; malignant peripheral nerve sheath tumor; neurofibroma; neurofibromatosis 1; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MALIGNANT TRANSFORMATION; MIDDLE AGED; NEUROFIBROMATOSIS; PHYSICAL DISEASE BY ANATOMICAL STRUCTURE; TUMOR VOLUME; WHOLE BODY MRI; WHOLE BODY PET; YOUNG ADULT; COMPLICATION; DIAGNOSTIC USE; METABOLISM; MULTIMODAL IMAGING; NERVE SHEATH TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; WHOLE BODY IMAGING;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84898549651     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182a757d3     Document Type: Article

References (32)

1. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-314.
2. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol. 2002;17:548-554.
3. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23:8422-8430.
4. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57: 2006-2021.
5. Duong TA, Sbidian E, Valeyrie-Allanore L, et al. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis. 2011;6:18.
6. Plotkin SR, Bredella MA, Cai W, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012;7: e35711.
7. Chhabra A, Soldatos T, Durand DJ, et al. The role of magnetic resonance imaging in the diagnostic evaluation of malignant peripheral nerve sheath tumors. Indian J Cancer. 2011;48:328-334.
8. Matsumine A, Kusuzaki K, Nakamura T, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol. 2009;135:891-900.
9. Warbey VS, Ferner RE, Dunn JT, et al. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009;36:751-757.
10. Moharir M, London K, Howman-Giles R, et al. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2010;37:1309-1317.
11. Bredella MA, Torriani M, Hornicek F, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007;189: 928-935.
12. Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a longterm clinical study. Ann Oncol. 2008;19:390-394.
13. Karabatsou K, Kiehl TR,Wilson DM, et al. Potential role of 18fluorodeoxyglucosepositron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery. 2009;65:A160YA170.
14. Shahid KR, Amrami KK, Esther RJ, et al. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1. J Surg Orthop Adv. 2011;20:132-135.
15. Bensaid B, Giammarile F, Mognetti T, et al. Utility of 18 FDG positron emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1 [in French]. Ann Dermatol Venereol. 2007;134:735-741.
16. Hsu CH, Lee CM,Wang FC, et al. Neurofibromawith increased uptake of [F-18]- fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion. Ann Nucl Med. 2003; 17:609-611.
17. Fisher MJ, Basu S, Dombi E, et al. The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol. 2008;87:165-171.
18. Ferner RE, Lucas JD, O'Doherty MJ, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68: 353-357.
19. Mautner VF, Brenner W, Funsterer C, et al. Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1. Anticancer Res. 2007;27:1819-1822.
20. Gaa J, Rummeny EJ, Seemann MD. Whole-body imaging with PET/MRI. Eur J Med Res. 2004;9:309-312.
21. Seemann MD, Meisetschlaeger G, Gaa J, et al. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res. 2006;11:58-65.
22. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51-57.
23. Lynch TM, Gutmann DH. Neurofibromatosis 1. Neurol Clin. 2002;20:841-865.
24. Cai W, Kassarjian A, Bredella MA, et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on wholebody MR images. Radiology. 2009;250:665-673.
25. Lim R, Jaramillo D, Poussaint TY, et al. Superficial neurofibroma: a lesion with unique MRI characteristics in patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2005;184:962-968.
26. Van Meerbeeck SF, Verstraete KL, Janssens S, et al. Whole body MR imaging in neurofibromatosis type 1. Eur J Radiol. 2009;69:236-242.
27. Tonsgard JH, Kwak SM, Short MP, et al. CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology. 1998;50:1755-1760.
28. Derlin T, Tornquist K, Munster S, et al. Comparative effectiveness of 18FFDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013;38: e19Ye25.
29. Salamon J, Derlin T, Bannas P, et al. Evaluation of intratumoural heterogeneity on (18)F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2013;40:685-692.
30. Mautner VF, Asuagbor FA, Dombi E, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neurooncol. 2008;10:593-598.
31. Tucker T, Wolkenstein P, Revuz J, et al. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005;65:205-211.
32. Treglia G, Taralli S, Bertagna F, et al. Usefulness of whole-body fluorine- 18-fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: a systematic review. Radiol Res Pract. 2012;2012: 431029.